UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 2, 2007
GENTA INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 0-19635 | 33-0326866 | |
| (Commission File Number) | (IRS Employer Identification No.) | |
| 200 Connell Drive Berkeley Heights, NJ |
07922 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| (908) 286-9800 | ||
| (Registrant’s Telephone Number, Including Area Code) | ||
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On February 2, 2007, Genta Incorporated, the “Company”, issued a press release announcing that the Company has completed its response to the 180-day List of Outstanding Issues from the European Medicines Agency (EMEA) regarding its Marketing Authorization Application (MAA) for Genasense® (oblimersen sodium), its lead anticancer product, for treatment of patients with advanced melanoma and anticipates that EMEA’s Committee on Human Medicinal Products (CHMP) will complete its review and issue its opinion regarding approval within the next 90 days.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
|
99.1 |
Press Release of the Company dated February 2, 2007 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GENTA INCORPORATED | |||
| Date: February 2, 2007 | By: |
/s/ RICHARD J. MORAN |
|
| Name: | Richard J. Moran | ||
| Title: | Senior Vice President, Chief
Financial Officer and Corporate Secretary |
||
EXHIBIT INDEX
|
Exhibit |
Description |
Sequentially |
| 99.1 | Press Release of the Company dated February 2, 2007 |